a public good project by the
Synthesis
Company
of California

© 2026

Monika Peeters | doi.page

0 works0 citations0 h-index

Monika Peeters

Janssen (Belgium)(BE)NIHR Southampton Biomedical Research Centre(GB)University of Southampton(GB)Technical University of Munich(DE)

Publications by Year

Research Areas

HIV/AIDS drug development and treatment, Hepatitis C virus research, HIV Research and Treatment, Liver Disease Diagnosis and Treatment, HIV/AIDS Research and Interventions

Most-Cited Works

→ Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial(2007)516 cited
→ Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial(2014)434 cited
→ Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial(2007)392 cited
→ Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial(2014)373 cited
→ Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study(2013)270 cited

→ Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial(2014)

254 cited

→ Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial(2013)233 cited

→ Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials(2009)192 cited

→ Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study(2016)189 cited

→ Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies(2010)184 cited